Modafinil in psychiatric disorders: The promising state reconsidered;Modafinil bij psychiatrische aandoeningen: De veelbelovende status opnieuw bekeken

Tijdschrift voor Psychiatrie

Volumn 52, Issue 11, 2010, Pages 763-773

  Joos, L ^a   Docx, L ^b   Schmaal, L ^c   Sabbe, B G C ^b   Dom, G ^d  

^a UNIVERSITY OF ANTWERP   (Belgium)

^b CAPRI ^*  (Belgium)

^c ACADEMIC MEDICAL CENTER   (Netherlands)

^d ANTWERP UNIVERSITY HOSPITAL   (Belgium)

Author keywords

Modafinil; Placebo controlled; Psychiatric disorders

Indexed keywords

MODAFINIL; PLACEBO;

ARTICLE; ATTENTION DEFICIT DISORDER; CLINICAL TRIAL; COCAINE DEPENDENCE; COGNITION; DEPRESSION; DRUG EFFICACY; DRUG SAFETY; FOLLOW UP; HUMAN; MENTAL DISEASE; MOOD DISORDER; SAMPLE SIZE; SCHIZOPHRENIA; SUBSTANCE ABUSE;

ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; BENZHYDRYL COMPOUNDS; CENTRAL NERVOUS SYSTEM STIMULANTS; COCAINE-RELATED DISORDERS; HUMANS; MENTAL DISORDERS; NARCOLEPSY; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SCHIZOPHRENIA; TREATMENT OUTCOME; WAKEFULNESS;

EID: 78649355784     PISSN: 03037339     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Amiri S, Mohammadi MR, Mohammadi M, e.a. Modafinil as a treatment for attention-deficit/hyperactivity disorder in children and adolescents: a double-blind, randomized clinical trial. Prog Neuropsychopharmacol Biol Psychiatry 2008; 32: 145-9.
2. Anderson IM, Ferrier IM, Baldwin RC, e.a. Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 2000 British Association for Psychopharmacology guidelines. J Psychopharmacol 2008; 22: 343-96.
3. Anderson AL, Reid MS, Li SH, e.a. Modafinil for the treatment of cocaine dependence. Drug Alcohol Depend 2009; 104: 133-9.
4. Ballon JS, Feifel D. A systematic review of modafinil: potential clinical uses and mechanisms of action. J Clin Psychiatry 2006; 67: 554-66. (Pubitemid 43764232)
5. Biederman J, Swanson J, Wigal S, e.a. Efficacy and safety of modafinil film-coated tablets in children and adolescents with attention- deficit/hyperactivity disorder: results of a randomized, double-blind, placebo-controlled, flexible-dose study. Pediatrics 2005; 116: 777-84.
6. Biederman J, Swanson J, Wigal S, e.a. A comparison of once-daily and divided doses of modafinil in children with attention-deficit/ hyperactivity Disorder: a randomized, double-blind, and placebo-controlled study. J Clin Psychiatry 2006; 67: 727-35.
7. Boellner S, Earl CQ, Arora S. Modafinil in children and adolescents with attention-deficit/hyperactivity disorder: a preliminary 8-week, open-label study. Curr Med Res Opin 2006; 22: 2457-65. (Pubitemid 46048361)
8. Candy M, Jones L, Williams R, Tookman A, King M. Psychostimulants for depression. CochraneDatabase Syst Rev 2008; 2: CD006722. DOI: 10.1002/14651858.CD006722.pub2.
9. Dackis C, Kampman K, Lynch K, e.a. A double-blind, placebo-controlled trial of modafinil for cocaine dependence. Neuropsychopharmacology 2005; 30: 205-11.
10. DeBattista C, Dogharmji K, Menza M, e.a. Adjunct modafinil for the short-term treatment of fatigue and sleepiness in patients with major depressive disorder: a preliminary double-blind, placebo-controlled study. J Clin Psychiatry 2003; 64: 1057-64.
11. DeBattista C, Lembke A, Solvason H, e.a. A prospective trial of modafinil as an adjunctive treatment of major depression. J Clin Psychopharmacol 2004; 24: 87-90.
12. Dunlop B, Crits-Christoph P, Evans D, e.a. Coadministration of modafinil and a selective serotonin reuptake inhibitor from the initiation of treatment of major depressive disorder with fatigue and sleepiness. J Clin Psychopharmacology 2007; 27: 614-9.
13. Farrow T, Hunter M, Haque R, e.a. Modafinil and unconstrained motor activity in schizophrenia. Br J Psychiatry 2006; 189: 461-2.
14. Fava M, Thase M, DeBattista C. A multicenter, placebo-controlled study of modafinil augmentation in partial responders to selective serotonin reuptake inhibitors with persistent fatigue and sleepiness. J Clin Psychiatry 2005; 66: 85-93.
15. Frye M, Grunze H, Suppes T, e.a. A placebo-controlled evaluation of adjunctive modafinil in the treatment of bipolar depression. Am J Psychiatry 2007; 164: 1242-9.
16. Greenhill L, Biederman J, Boellner S, e.a. A randomized, double-blind, placebo-controlled study of modafinil film-coated tablets in children and adolescents with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 2006; 45: 503-11. (Pubitemid 43756179)
17. Hart C, Haney M, Vosburg S, e.a. Smoked cocaine self-administration is decreased by modafinil. Neuropsychopharmacol 2008; 33: 761-8.
18. Hunter M, Ganesan V, Wilkinson I, e.a. Impact of modafinil on prefrontal executive function in schizophrenia. Am J Psychiatry 2006; 163: 2184-6.
19. Kahbazi M, Ghoreishi A, Rahiminejad F, e.a. A randomized, double-blind and placebo-controlled trial of modafinil in children and adolescents with attention deficit and hyperactivity disorder. Psychiatry Res 2009; 168: 234-7.
20. Kumar R. Approved and investigational uses of modafinil: an evidence-based review. Drugs 2008; 68: 1803-9.
21. Markowitz P, Wagner S. An open-label trial of modafinil in patients with partial response to antidepressant therapy. J Clin Psychopharmacol 2003; 23: 207-9.
22. McGregor C, Srisurapanont M, Mitchell A, e.a. Symptoms and sleep patterns during inpatient treatment of methamphetamine withdrawal: a comparison of mirtazapine and modafinil with treatment as usual. J Subst Abuse Treat 2008; 35: 334-42.
23. Minzenberg MJ, Carter CS. Modafinil: a review of neurochemical actions and effects on cognition. Neuropsychopharmacol 2008; 33: 1477-502.
24. Pierre J, Peloian J, Wirshing D, e.a. A randomized, double-blind, placebo-controlled trial of modafinil for negative symptoms in schizophrenia. J Clin Psychiatry 2007; 68: 705-10.
25. Rosenthal M, Bryant S. Benefits of adjunct modafinil in an open-label, pilot study in patients with schizophrenia. Clin Neuropharmacol 2004; 27: 38-43.
26. Rugino T, Copley T. Effects of modafinil in children with attention-deficit/hyperactivity disorder: an open-label study. J Am Acad Child Adolesc Psychiatry 2001; 40: 230-5.
27. Rugino T, Samsock T. (2003). Modafinil in children with attention-deficit hyperactivity disorder. Pediatr Neurol 2003; 29: 136-42.
28. Schnoll RA, Wileyto EP, Pinto A, e.a. A placebo-controlled trial of modafinil for nicotine dependence. Drug Alcohol Depend 2008; 98: 86-93.
29. Sevy S, Rosenthal M, Alvir J, e,a. Double-blind, placebo-controlled study of modafinil for fatigue and cognition in schizophrenia patients treated with psychotropic medications. J Clin Psychiatry 2005; 66: 839-43.
30. Shearer J, Darke S, Rodgers C, e.a. A double-blind, placebo-controlled trial of modafinil (200 mg/day) for metamphetamine dependence. Addiction 2009; 104: 224-33.
31. Sofuoglu M, Waters AJ, Mooney M. Modafinil and nicotine interactions in abstinent smokers. Hum Psychopharmacol 2008; 23: 21-30.
32. Spence S, Green R, Wilkinson I, e.a. Modafinil modulates anterior cingulate function in chronic schizophrenia. Br J Psychiatry 2005; 187: 55-61.
33. Swanson J, Greenhill L, Lopez F, e.a. Modafinil film-coated tablets in children and adolescents with attention-deficit/hyperactivity disorder: results of a randomized, double-blind, placebo-controlled, fixed-dose study followed by abrupt discontinuation. J Clin Psychiatry 2006; 67: 137-47. (Pubitemid 43213294)
34. Taylor F, Russo J. (2000). Efficacy of modafinil compared to dextroamphetamine for the treatment of attention deficit hyperactivity disorder in adults. J Child Adolesc Psychopharmacol 2000; 10: 311-20.
35. Thase ME, Fava MD, DeBattista C, e.a. Modafinil augmentation of SSRI therapy in patients with major depressive disorder and excessive sleepiness and fatigue: a 12-week, open-label, extension study. CNS Spectrums 2006; 11: 93-102.
36. Turner D, Clark L, Dowson J, e.a. Modafinil improves cognition and response inhibition in adult attention-deficit/hyperactivity disorder. J Biol Psychiatry 2004a; 55: 1031-40.
37. Turner D, Clark L, Pomarol-Clotet E, e.a. Modafinil improves cognition and attentional set shifting in patients with chronic schizophrenia. Neuropsychopharmacol 2004b; 29: 1363-73.
38. Vaishnavi S, Gadde K, Alamy S, e.a. Modafinil for atypical depression: effects of open-label and double-blind discontinuation treatment. J Clin Psychopharmacol 2006; 26: 373-8.
39. Vansickel A, Fillmorex M, Hays L, e.a. Effects of potential agonist-replacement therapies for stimulant dependence on inhibitory control in cocaine abusers. Am J Drug Alcohol Abuse 2008; 34: 293-305. (Pubitemid 351572454)
40. Volkow ND, Fowler JS, Logan J, e.a. Effects of modafinil on dopamine and dopamine transporters in the male human brain: clinical implications. JAMA 2009; 301: 1148-54.